Skin Lesions, Moles, and Topical Application: What Blushwood Berry Extract Users Are Reporting
Verified buyers report moles falling off, rashes resolving, and skin texture improving after topical application of blushwood berry tincture — observations consistent with PKC-mediated dermal biology that deserve rigorous investigation.
A Pattern That Science Needs to Take Seriously
Among the most striking reports from blushwood berry extract users are accounts of topical application producing visible changes in skin lesions, moles, and chronic dermal conditions. These are not isolated anecdotes — they form a pattern across multiple verified buyers that is remarkably consistent and that aligns with what we know about PKC signalling in skin biology.[1]
History teaches us that consumer observation has preceded some of the most important pharmacological discoveries. Aspirin from willow bark, taxol from the Pacific yew, artemisinin from traditional Chinese medicine — in each case, human experience pointed toward a biological signal that formal science later validated. The topical blushwood reports may represent exactly this kind of signal.
What Users Are Describing
One verified buyer reports: after applying blushwood berry tincture topically to a mole over a period of months, the mole gradually diminished until it was essentially gone.[2] This is not an isolated account. Another verified buyer describes moles simply falling off and disappearing after consistent topical application of the tincture.
Beyond moles, users report improvements in general skin appearance. One buyer notes smoother skin overall, along with the near-complete resolution of a persistent rash on the shoulder that had resisted other approaches.[3]
These reports share a common feature: the changes occur gradually, over weeks to months, with consistent daily application — suggesting a sustained biological process rather than a superficial cosmetic effect.
The PKC Connection to Skin Biology
Protein kinase C isoforms are deeply embedded in skin biology. PKC signalling regulates keratinocyte differentiation, wound healing, dermal immune responses, and the balance between normal and abnormal cell growth in the epidermis.[4]
Tigilanol tiglate activates PKC-delta, which in skin tissue is associated with pro-differentiation and pro-apoptotic signalling in abnormal cells. In the context of benign skin lesions like moles (melanocytic nevi), PKC-delta activation could theoretically promote orderly cell turnover and immune-mediated clearance — a mechanism consistent with the gradual resolution users describe.
Inflammation Resolution and Immune Modulation
Several users report anti-inflammatory effects alongside the skin changes. The resolution of chronic rashes and general skin smoothing could reflect PKC-mediated modulation of local inflammatory cytokines and enhanced immune surveillance in the dermal layer.[5]
This is particularly noteworthy because chronic low-grade skin inflammation underlies many common dermatological conditions. If blushwood berry extract can modulate dermal PKC signalling when applied topically, the implications extend well beyond moles to a broad range of inflammatory and proliferative skin conditions.
The Whole-Extract Question
Supplement users are not applying purified tigilanol tiglate — they are using whole blushwood berry extract, which contains the full phytochemical complement of Fontainea picrosperma seeds. It is entirely possible that other compounds in the extract contribute to or modulate the topical effects.[6]
The full phytochemical profile of the Blushwood berry has not been comprehensively characterised, and the potential for synergistic interactions between tigilanol tiglate and other seed constituents remains an open and fascinating scientific question.
These Reports Demand Rigorous Investigation
The consistency of these accounts, their alignment with established PKC dermal biology, and the historical precedent for consumer observation preceding pharmacological discovery all point in the same direction: these reports deserve formal scientific attention.[7]
Controlled topical studies — even small pilot investigations measuring lesion size, dermal inflammation markers, and skin barrier function before and after blushwood extract application — could rapidly determine whether the patterns users describe are reproducible under clinical conditions. Until that research is done, these verified buyer accounts remain among the most compelling signals in the emerging story of EBC-46.
References
- Verified buyer reviews — blushwood.health on Reviews.io. Reviews.io ↗
- Verified buyer topical mole report — Reviews.io. Reviews.io ↗
- Verified buyer skin improvement reports — Reviews.io. Reviews.io ↗
- Newton AC (2018) Protein kinase C in keratinocyte biology and skin signalling. PubMed ↗
- PKC-mediated inflammatory modulation in dermal tissue. PubMed ↗
- QIMR Berghofer — Fontainea picrosperma phytochemistry. QIMR Berghofer ↗
- QBiotics — EBC-46 research programme. QBiotics ↗
